Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Rating) – Research analysts at Oppenheimer lifted their FY2023 EPS estimates for shares of Aldeyra Therapeutics in a note issued to investors on Wednesday, June 8th. Oppenheimer analyst J. Kim now anticipates that the biotechnology company will earn ($0.94) per share for the year, up from their previous forecast of ($0.97). The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($1.37) per share. Oppenheimer also issued estimates for Aldeyra Therapeutics’ FY2025 earnings at $0.56 EPS.
Several other research analysts have also issued reports on the stock. StockNews.com initiated coverage on shares of Aldeyra Therapeutics in a research note on Thursday, March 31st. They issued a “sell” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of Aldeyra Therapeutics in a research note on Wednesday, April 27th. Berenberg Bank initiated coverage on shares of Aldeyra Therapeutics in a research note on Tuesday, May 24th. They issued a “buy” rating and a $28.00 price target for the company. Finally, Citigroup increased their price target on shares of Aldeyra Therapeutics from $21.00 to $26.00 and gave the stock a “buy” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $19.00.
Shares of NASDAQ ALDX opened at $3.57 on Monday. The company has a current ratio of 13.60, a quick ratio of 13.60 and a debt-to-equity ratio of 0.08. Aldeyra Therapeutics has a 12 month low of $2.36 and a 12 month high of $12.73. The firm has a market capitalization of $208.13 million, a PE ratio of -3.22 and a beta of 1.64. The firm has a fifty day simple moving average of $3.40 and a two-hundred day simple moving average of $4.17.
Aldeyra Therapeutics (NASDAQ:ALDX – Get Rating) last announced its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.02. During the same quarter in the previous year, the firm posted ($0.25) EPS.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in shares of Aldeyra Therapeutics by 0.4% in the third quarter. Geode Capital Management LLC now owns 901,917 shares of the biotechnology company’s stock worth $7,918,000 after buying an additional 3,400 shares during the last quarter. Morgan Stanley boosted its holdings in shares of Aldeyra Therapeutics by 29.0% in the first quarter. Morgan Stanley now owns 16,375 shares of the biotechnology company’s stock worth $194,000 after buying an additional 3,680 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Aldeyra Therapeutics by 3.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 128,385 shares of the biotechnology company’s stock worth $514,000 after buying an additional 3,699 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Aldeyra Therapeutics by 21.3% in the first quarter. JPMorgan Chase & Co. now owns 22,835 shares of the biotechnology company’s stock worth $101,000 after buying an additional 4,012 shares during the last quarter. Finally, Kestra Advisory Services LLC boosted its holdings in shares of Aldeyra Therapeutics by 33.4% in the fourth quarter. Kestra Advisory Services LLC now owns 16,809 shares of the biotechnology company’s stock worth $67,000 after buying an additional 4,212 shares during the last quarter. 62.94% of the stock is currently owned by hedge funds and other institutional investors.
Aldeyra Therapeutics Company Profile (Get Rating)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
See Also
Receive News & Ratings for Aldeyra Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aldeyra Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
